At the beginning of the session, Mihaela presented AutoPrognosis 2.0 to an international panel of clinical experts who discussed opportunities and impacts of the tool. This was followed by Dr Eoin McKinney, MD, who gave the clinical perspective on the impact of AutoPrognosis. Then, we had a look at an intriguing case study together with Dr Thomas Callender, MSc MRCP, Wellcome Trust Clinical Training Fellow and Public Health Physician at UCL who has used a version of our tool already.

Finally, we had a round table discussion with experts from the field to explore the opportunities and advances our tool offers for clinicians. Our guests were:

- Prof Donald E. Ingber, MD, PhD (Founding Director, Wyss Institute for Biologically Inspired Engineering at Harvard University; Judah Folkman Professor of Vascular Biology, Harvard Medical School & Vascular Biology Program, Boston Children’s Hospital; Hansjörg Wyss Professor of Bioinspired Engineering, Harvard School of Engineering and Applied Sciences)

- Prof Suetonia Palmer, MB ChB, PhD, FRACP (Professor of Medicine, University of Otago, New Zealand; Deputy Dean, University of Otago, Christchurch; Renal Physician, Christchurch Hospital, New Zealand)

- Dr Paul Goldsmith, MA, BM, BCh, MRCP, PhD (Consultant Neurologist NHS Clinical Senate; Non-executive director of Medicines and Healthcare Products Regulatory Agency (MHRA); Non-executive director of MDU Ltd and MDU Investments Ltd; President, Chief Medical and Innovation Officer, Closed Loop Medicine Ltd; Trustee Radix Big Tent Foundation)

Our panelists answered a number of questions posed by Mihaela and the audience.